Short answer
Zimmer Biomet (ZBH) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $2.1B (up 3.1% year over year) with net income of $192M.
Q3 2026 key financials · XBRL
- Revenue
- $2.1B
- +3.1% YoY · −5.2% QoQ
- Net income
- $192M
- −17.0% YoY · −3.4% QoQ
- Operating margin
- 14.9%
- EPS (diluted)
- $1.00
- −13.8% YoY · −2.9% QoQ
Source: XBRL data from the Zimmer Biomet (ZBH) Q3 2026 10-Q on SEC EDGAR. USD.
Zimmer Biomet Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $2,062.9M, up 3.1% from $2,001.4M YoY
- Operating margin 14.9% vs 17.6% YoY, net earnings $191.6M vs $230.9M
- Best category Technology & Data, Bone Cement and Surgical, $180.6M, up 11.9%; worst Knees, $767.5M, down 3.1%
- Nine-month operating cash flow $1,367.2M vs $1,179.7M; share repurchases $579.3M
- 2026 sales-growth guidance 4.4% to 4.9%; headwinds from pricing pressure, inflation and commercial investments
Risk Factors
- No material changes to 2025 Form 10-K risk factors disclosed
- Carried-forward risks could materially affect business, financial condition and results of operations
- Additional unknown or currently immaterial risks could become materially adverse
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Zimmer Biomet quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.